Mimedx (MDXG) Interest Coverage Ratio (2011 - 2026)
Mimedx (MDXG) posted Interest Coverage Ratio of 47.84 for Q2 2026, down 19.83% sequentially from 39.92 in Q1 2026, and down 344.03% YoY from 19.6 in Q2 2025.
Mimedx (MDXG) Interest Coverage Ratio (2011 - 2026) Analysis & Trends
Mimedx has reported Interest Coverage Ratio for 16 years, with the latest figure at 47.84 in Q2 2026.
- Quarterly Interest Coverage Ratio fell 344.03% year-over-year to 47.84 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 11.21 (down 83.49% YoY) and the FY2025 annual result came in at 5.76, down 61.44% from the prior year.
- Interest Coverage Ratio eased to 47.84 in Q2 2026 per MDXG's latest filing, from 39.92 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 30.36 in Q3 2025 and troughed at 47.84 in Q2 2026.
- A 5-year average of 1.2 and a median of 6.3 in 2022 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2022 and 2024: Interest Coverage Ratio sank 2203.64% in 2022, then surged 2645.88% in 2024.
- Over 5 years, Interest Coverage Ratio stood at 6.23 in 2022, then jumped by 43.76% to 8.96 in 2023, then slumped by 271.61% to 15.37 in 2024, then soared by 292.55% to 29.6 in 2025, then slumped by 261.61% to 47.84 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 47.84, 39.92, and 29.6 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn | -47.84 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -47.84 |
| Mar 31, 2026 | -39.92 |
| Dec 31, 2025 | 29.60 |
| Sep 30, 2025 | 30.36 |
| Jun 30, 2025 | 19.60 |
| Mar 31, 2025 | 13.48 |
| Dec 31, 2024 | -15.37 |
| Sep 30, 2024 | 6.36 |
| Jun 30, 2024 | 13.59 |
| Mar 31, 2024 | 5.56 |
| Dec 31, 2023 | 8.96 |
| Sep 30, 2023 | 6.61 |
| Jun 30, 2023 | 6.65 |
| Mar 31, 2023 | -0.22 |
| Dec 31, 2022 | 6.23 |
| Sep 30, 2022 | -5.59 |
| Jun 30, 2022 | -8.31 |
| Mar 31, 2022 | -8.14 |
| Dec 31, 2021 | 1.09 |
| Sep 30, 2021 | -0.92 |